Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
Deal Summary On June 9, 2026, GSK announced the acquisition of Nuvalent for $11 billion — paying $124 per share, a 40% premium over the prior trading price. The deal
On June 8, 2026, Roche and Nurix Therapeutics announced a clinical collaboration for bexobrutideg — a BTK protein degrader in development for chronic lymphocytic leukemia and other blood cancers. Roche
We recently rated a one-time gene therapy for Duchenne muscular dystrophy in young boys. The Phase 3 trial was well designed. We looked at the primary endpoint. It was not
Summary GSK announced the $11 billion acquisition of Nuvalent on June 9, 2026, gaining two experimental lung cancer drugs under FDA review. Zidesamtinib targets ROS1-positive NSCLC; neladalkib targets ALK-positive NSCLC.
Summary Incyte agreed to acquire Vega Therapeutics for $1.25 billion upfront on June 8, 2026, gaining VGA039, a subcutaneous monthly injection for von Willebrand disease (VWD), in Phase 3 testing.
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for
Summary Roche announced a $700 million upfront collaboration with Nurix Therapeutics on June 8, 2026, to codevelop bexobrutideg, a BTK protein degrader, for blood cancers including CLL and autoimmune conditions.
We have just published a MARA Rating for a one-time gene therapy for a rare childhood disease. The trials answered one question clearly: do treated patients do better than untreated
We recently completed a MARA Rating for a treatment for Barth syndrome — a rare, life-threatening disease that affects young men and has no established disease-modifying therapy. The randomized trial